Effective May 17th, 2021 our new address is 3201 Cross Timbers Rd Bldg 4 Ste 300Flower Mound, TX 75028
Read More
Retinopathy of prematurity (ROP) is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness.
Read More
The Knights Templar Eye Foundation, Inc. is proud to announce that they have established an endowment at Vanderbilt University Medical Center (VUMC) called -“Knights Templar Eye Foundation Directorship in Pediatric Vision Research.” The Foundation has made a $2 million contribution which is being matched dollar for dollar by VUMC honoring Dr. John S. Penn who will be the inaugural holder of a Directorship supported by this endowment.
Read More
Our meeting ended with 28 total Competitive Renewal & Career Starter grants for a total of $1,957,897 that was recommended by the SAC doctors and later that night approved by the KTEF SAC committee.
Read More
This data will provide an essential molecular entry point from which to further develop methods to promote retinal regeneration through stem cell transplantation and likely have significant influence on the field of retinal regenerative medicine.
Read More
His research and study will include another mouse model for RP, in which he will be able to model a prospective gene therapy strategy and perform a rigorous feasibility analysis with my cutting-edge microscopy techniques to see if this strategy could rescue and save the diseased retina.
Read More
Juvenile glaucoma is usually caused by increased pressure inside the eye, which is due to resistance to the flow of the normal circulation of the fluid within the eye. The buildup of pressure in the eye can damage the visual sensing structures in the back of the eye, leading to blindness. The goal of this project is to better understand the mechanisms involved in the buildup of pressure in the eye. In his research he will be using human cells as well as a mouse model that has similar characteristics to those patients with juvenile glaucoma.
Read More
The proposed research seeks to understand the critical signaling events with the MAPK network that bring about RGC death and thus reveal new targets for pediatric glaucoma intervention. It is our hope that these new insights will contribute to new treatment strategies to prevent vision loss.
Read More
Congenital glaucoma is an eye disease that affects children between the ages of birth and three years. Although the disease is rare, it is one the significant causes of childhood blindness. Congenital glaucoma is usually caused by increased pressure inside the eye, which is due to developmental abnormalities in the front of the eye. The buildup of pressure in the eye compresses the visual sensing structures in the back of the eye, which leads to blindness. The goal of this project is to better understand the mechanisms involved in glaucomatous injury to the eye.
Read More
Pediatric glaucoma is a potentially blinding disease, accounting for about 18% of blindness in blind institutions and 5% of overall pediatric blindness worldwide.
Read More
Dr. Guo proposes to use a new CRISPR-based gene regulation technology to overcome these barriers and develop a novel type of gene therapy, with the longterm goal of generating new treatments for blinding diseases in children.
Read More
This work will advance the understanding of the fundamental molecular mechanisms underlying fovea formation and contribute to the development of newer therapies for treating congenital foveal hypoplasia conditions.
Read More
On October 10, 2020 at the 178th Annual Conclave in Ohio thanks to the generosity of the Sir Knights of Forest City Commandery No. 40 made a major contribution to make the Grand Commandery of Ohio now 200% Life Sponsorships.
Read More
The goal of this project is to evaluate a novel technology, eye tracking, as a method for visual assessment in children with CVI. Eye tracking utilizes an infrared camera to capture eye movements while children view pictures and videos. This allows the doctor to non-invasively determine what a child with CVI is able to see, without requiring active participation.
Read More
The goals of the study are to initially understand the cause of the disease by studying available models and test gene therapy to replace the defective gene to investigate whether this will prevent retinopathy in the disease model. The ultimate aim is to develop new therapies which will prevent vision loss in children affected by Danon disease.
Read More
Xerophthalmia in vitamin A deficiency (VAD) is a major cause of pediatric blindness. Children with vitamin A deficiency develop severe corneal inflammation and opacification that can lead to blindness or loss of the eye.
Read More
Funding for research in pediatric eye disorders is extremely important and critically needed. The Knights Templar Eye Foundation is one of the few organizations that provide support for pediatric ophthalmology research.
Read More
A few short months ago, our world changed. But our obligation as Christian Masons has not. Whether we are assisting our shut-in brothers and neighbors with groceries or household chores or supporting doctors and scientists working to find a key that will allow a child who has never stared in amazement at a rainbow to see one for the first time, we always find a way to wrap others "in the broad mantle of a Mason's charity." There is no doubt in my mind we will continue to do so.
Read More
Dr. Zhengping Hu from Schepens Eye Research Institute, Harvard Medical School in Boston, MA was awarded a $65,000 check to support her research in Retinopathy of Prematurity (ROP) which is a leading cause of blindness in premature and low birth weight infants.
Read More
Many current and past grand officers of the Grand Commandery of Ohio along with many Constituent officers traveled to the Cole Eye Institute at the Cleveland Clinic to present a $65,000 research grant check to Joseph Fogerty, Ph.D., to study a common blinding disorder in children known as Leber’s Congenital Amaurosis (LCA)
Read More